Navigation Links
ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Date:12/11/2007

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ --

- TB-402 Shows Clear Promise as a Stable Long-acting Anticoagulant for the Prevention of Thromboembolic Disorders.

ThromboGenics NV (Euronext Brussels:THR), a biotechnology company focused on vascular and eye disease, announced that the results of the first Phase I trial of TB-402 were presented yesterday at the prestigious American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Georgia, USA. TB-402 is being co-developed in collaboration with BioInvent International (Nordic Exchange: BINV).

TB-402 is a recombinant human monoclonal antibody which has shown a beneficial partial inhibition of the blood coagulation Factor VIII. Its long half life of approximately three weeks enables it to produce a stable and long-acting inhibition. This indicates well-controlled inhibition of Factor VIII activity with low risk of spontaneous bleeding, thus avoiding the possibility of overdose and the need for patient monitoring.

These unique features may be of major clinical significance, as it suggests that a product with an excellent safety profile, with ease of administration and compliance superior to alternative anticoagulants, can be developed. The preliminary results of the initial Phase I study were previously communicated in a Press Release issued September 7, 2007.

The Phase I trial presented at ASH was a randomized, single-dose, placebo-controlled, dose escalation trial in healthy male volunteers. 56 subjects were enrolled into the trial, including both younger age (18-45) and older age (55-76) volunteers. Results of the trial show that TB-402 is both safe and well-tolerated. No serious adverse events related to TB-402 were reported. In addition, there were no major bleeding complications, with the overall incidence being similar in both the TB-402 treated group and the patients who received placebo.

The pharmacokinetic analysis undertaken as part of the study
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia ... quantitative data from a study of the cost and ... the 50 th Annual Meeting of the European ... poster session today, Christian Frois , Ph.D., of ... a series of planned Intarcia-sponsored, retrospective studies to characterize ...
(Date:9/17/2014)... FORT LAUDERDALE, Fla. , Sept. 17, 2014 ... signed an agreement to form a Special Purpose Vehicle in ... based Jatropha centric agro energy company. The SPV shall ... U.S. registered entity with AFAI as majority shareholder. The SPV ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... , Sept. 17, 2014 Veracyte, Inc. ... company pioneering the field of molecular cytology, today announced ... officer. Mr. Hall joined Veracyte in 2010 ... entry into endocrinology. Since 2012, he has led sales, ... managed care and billing functions. As chief operating officer, ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... cites Dr. Lanza for ,Courage Under Fire, ... (OTC Bulletin Board: ACTC) is proud to announced ... Research and Scientific,Development, has been recognized for his ... in the current issue of PharmaVOICE (cover,story July/August ...
... New USA Subsidiary Meets Demand for SLIM Search(TM) ... Aug. 21 Supporting the growing,demand for its ... Ltd. announces the opening of its new sales, ... Mission Viejo,California. SLIM Search, Inc. is the leading ...
... LOUIS, Aug. 20 The MattsonJack Group, Inc.,(MattsonJack), ... Dhawan M.D.,M.B.A., M.P.H. to Medical Director for MattsonJack. ... joined MattsonJack in September 2000 as a consultant ... M.B.A. from the,University of Missouri -- Kansas City. ...
Cached Biology Technology:Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3Cartesian Gridspeed Opens Subsidiary Operation in North America 2Cartesian Gridspeed Opens Subsidiary Operation in North America 3Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 2Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 3
(Date:9/17/2014)... started in 2000 as an EC-FP5 four-year project, delivering ... steady progress and successful participations in several EC projects, ... Observation Network project (EU BON), to increase the ... and to extend the general dissemination of the Fauna ... has applied its novel e-Publishing tools to prepare ...
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... Mich. Mutations in the human retinoblastoma protein gene ... State University scientists have turned to fruit fly eyes ... , In a paper featured on the cover ... Biological Chemistry , Michigan State University researchers provide the ... to those present in the human cancer gene, said ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2
... farmers in Riau province, Sumatra, have been blamed for ... Malaysia. But scientists in Indonesia have added a third ... to land for oil palm and clear it by ... World Agroforestry Centre, who have been studying land conversion ...
... in Belgium has shown that low-cost IVF for ... effective, with delivery rates not much different from ... study, say the investigators, suggests that infertility care ... IVF methodology can be significantly simplified and result ...
... enough milk to breastfeed? A new study by scientists ... California Davis adds to their previous research implicating insulin,s role ... describe how the human mammary gland becomes highly sensitive to ... to get an accurate picture of how specific genes are ...
Cached Biology News:Less haze in Singapore as the cause becomes clearer and more complex 2IVF for 200 euro per cycle 2IVF for 200 euro per cycle 3New study reveals important role of insulin in making breast milk 2New study reveals important role of insulin in making breast milk 3
...
... The Bio-Plex maintenance, calibration, ... is a custom 96-well plate ... validation, and calibration procedures using ... This MCV plate is for ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... PCR detection system holds 48 x 0.2 ml ... 48 LEDs independently excites fluorescence (470-500 nm) for ... detects emitted light (523-543 nm and 540-700 nm). ... cycler, whose Peltier heat pumps provide superb thermal ...
Biology Products: